logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Stefanie S. Jeffrey

Stanford University
H指数:60
被引数:4.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part

Linnovate：一项使用 lurbinectedin 联合 ipilimumab 和 nivolumab 治疗晚期软组织肉瘤的安全性/有效性 I/II 期研究（NCT05876715）——I期部分中期分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Gordon, E. M.; Chawla, S. P.; Omelchenko, N.; Jeffrey, S.; Agarwal, A. D.; Chawla, N. S.; Alcala, V. S. Chua; Quon, D.; Wong, S.
Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma

SAINT研究进展：一项关于在既往治疗过的软组织肉瘤中使用曲贝替定（T）联合伊匹木单抗（I）和纳武利尤单抗（N）的II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Agarwal, A. D.; Jeffrey, S.; Cechini, R.; Kumar, V.; Omelchenko, N.; Ballon, J.; Moradkhani, A.; Alcala, V. S. Chua; Chawla, N. S.; Mahesh, S.; Chawla, S. P.; Gordon, E. M.
Blessed: Expanded yccess for DeltaRex-G in vivo gene therapy for sarcoma, pancreas and breast cancer (NCT04091295) and other solid malignancies (IND# 19130)

Blessed：扩展了DeltaRex-G在体内基因治疗中的适应症范围，适用于肉瘤、胰腺癌和乳腺癌（NCT04091295）以及其他实体恶性肿瘤（IND# 19130）。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Chawla, S. P.; Isacoff, W.; Jeffrey, S.; Omelchenko, N.; Chawla, N. S.; Agarwal, A. D.; Haroun, G.; Carter, R.; Reed, R.; Swaney, W.; Hall, F. L.; Federman, N.; Chang, P.; Song, P.; Gordon, E. M.
Update on gallant: A phase II study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab in previously treated sarcoma

关于Gallant的更新：一项使用常规剂量吉西他滨、多柔比星和多西他赛联合纳武利尤单抗治疗既往接受过治疗的肉瘤的II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Chawla, N. S.; Cechini, R.; Kumar, V.; Agarwal, A. D.; Jeffrey, S.; Omelchenko, N.; Ballon, J.; Haroun, G.; Alcala, V. S. Chua; Moradkhani, A.; Chawla, S. P.; Gordon, E. M.
Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene

人工智能分析显示肉瘤肿瘤中CCNG1表达增强，这是deltarex-g肿瘤靶向逆转录载体编码CCNG1抑制剂基因的新型生物标志物

ANNALS OF ONCOLOGY
IF65.4
2023-10-010
OAAI
Chawla, S. P.; Omelchenko, N.; Eid, C.; Jeffrey, S.; Shekhovtsova, Z.; Suryamohan, K.; Younesi, E.; Omelchenko, A.; Ahari, A.; Valencia, C.; Chawla, N. S.; Brigham, D.; Gordon, E. M.

研究方向

暂未获取到该数据
C
Corinne Renier
H 指数:21论文数:56被引数:2,134
E
Elodie Sollier
H 指数:19论文数:48被引数:3,011
J
James Che
H 指数:15论文数:40被引数:1,702
V
Vishnu C. Ramani
H 指数:25论文数:48被引数:3,368
A
Anne‐Lise Børresen‐Dale
H 指数:105论文数:595被引数:7.7万
M
Melanie Triboulet
H 指数:8论文数:28被引数:443
M
Monica Nicolau
H 指数:17论文数:61被引数:3,661
D
Debra M. Ikeda
H 指数:47论文数:245被引数:7,255
P
Patrick O. Brown
H 指数:152论文数:383被引数:16.9万
B
Bruce L. Daniel
H 指数:47论文数:285被引数:7,208